Liquidia Technologies Added to Russell 2000®, 3000® and Microcap® Indexes

RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2018 (GLOBE NEWSWIRE) -- , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its to transform the lives of patients, today announced that it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after market close on September 21, 2018, as part of Russell’s quarterly addition of companies with recent initial public offerings.

The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000. Membership in the Russell 2000 Index includes automatic inclusion in the appropriate growth and value indexes, such the Russell Microcap Index. The Russell Microcap Index represents small-cap and micro-cap stocks.

“Inclusion in the Russell 2000, Russell 3000 and Russell Microcap Indexes offers the opportunity to broaden Liquidia’s presence within the investment community,” said Neal Fowler, Chief Executive Officer of Liquidia. “We are pleased to be added to these indexes and believe that we are well-positioned following our successful initial public offering in July.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Indexes go to the “Russell Reconstitution” section on the .

About Liquidia Technologies

(“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: for the treatment of pulmonary arterial hypertension and for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology. For more information visit our website at .

Forward-Looking Statements

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “will” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved and we undertake no duty to update our goals.



Contact:

Jennifer Almond

Director, Investor Relations & Corporate Communications

919.328.4389